About the Authors

Kousei Ohshima

Affiliations Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan, Department of Integrated Medicine and Informatics, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan

Masaki Mogi

Affiliation Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan

Fei Jing

Affiliation Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan

Jun Iwanami

Affiliation Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan

Kana Tsukuda

Affiliation Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan

Li-Juan Min

Affiliation Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan

Akiyoshi Ogimoto

Affiliation Department of Integrated Medicine and Informatics, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan

Björn Dahlöf

Affiliation Department of Medicine, Sahlgrenska University Hospital/Östra, University of Gothenburg, Gothenburg, Sweden

Ulrike M. Steckelings

Affiliation Center for Cardiovascular Research, Institute of Pharmacology, Charité University Medicine, Berlin, Germany

Tomas Unger

Affiliation CARIM - School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands

Jitsuo Higaki

Affiliation Department of Integrated Medicine and Informatics, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan

Masatsugu Horiuchi

horiuchi@m.ehime-u.ac.jp

Affiliation Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan

Competing Interests

TU has modest interest in Vicore Pharma, and BD and TU have received speaker and consulting fees from Vicore Pharma. BD also has significant interest in Mintage Scientific, the owner of Vicore Pharma. The Compound 21 used in this study was provided by Vicore Pharma. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: MH. Performed the experiments: KO FJ JI KT LM. Analyzed the data: KO. Wrote the paper: KO MM MH. Read and approved the manuscript: MM AO BD US TU JH MH.